Liminal BioSciences Inc (LMNL) - Financial and Strategic SWOT Analysis Review

August 2021 | 53 pages | ID: PDD20A94175EN
GlobalData

Abstracts

Liminal BioSciences Inc (LMNL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Liminal BioSciences Inc (Liminal), formerly ProMetic Life Sciences Inc, is a biopharmaceutical company that focuses on plasma-derived therapeutics and small-molecule drug development. The company develops products for the treatment for fibrosis, including respiratory, liver, and kidney diseases. Liminal develops drug candidates based on two drug discovery platforms: small molecule therapeutics (PSMT), and plasma-derived therapeutics. It intends to capitalize on its drug discovery platform and knowledge base to build an early-stage drug portfolio. The company owns research and development facilities in the UK, the US, and Canada, and has manufacturing facilities in Canada. Liminal is headquartered in Laval, Quebec, Canada.

Liminal BioSciences Inc Key Recent Developments

Jun 04,2021: Liminal Announces Voting Results of Its 2021 Annual and Special General Meeting of Shareholders (AGM)
May 17,2021: Liminal BioSciences Reports First Quarter 2021 Financial Results
Mar 24,2021: Liminal BioSciences Reports Fourth Quarter and Year End 2020 Financial Results
Jan 12,2021: Liminal BioSciences receives FDA approval for its US-based plasma collection center
Nov 12,2020: Liminal BioSciences reports third quarter financial results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Liminal BioSciences Inc - Key Facts
Liminal BioSciences Inc - Key Employees
Liminal BioSciences Inc - Key Employee Biographies
Liminal BioSciences Inc - Major Products and Services
Liminal BioSciences Inc - History
Liminal BioSciences Inc - Company Statement
Liminal BioSciences Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Liminal BioSciences Inc - Business Description
Business Segment: Plasma-derived Therapeutics
Performance
Business Segment: Plasma-derived therapeutics segment
Overview
Business Segment: Small Molecule Therapeutics
Overview
Performance
Geographical Segment: Canada
Performance
Geographical Segment: Norway
Performance
Geographical Segment: The UK
Performance
Geographical Segment: The US
Performance
R&D Overview
Liminal BioSciences Inc - Corporate Strategy
Liminal BioSciences Inc - SWOT Analysis
SWOT Analysis - Overview
Liminal BioSciences Inc - Strengths
Liminal BioSciences Inc - Weaknesses
Liminal BioSciences Inc - Opportunities
Liminal BioSciences Inc - Threats
Liminal BioSciences Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Liminal BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Liminal BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Liminal BioSciences Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Jun 04, 2021: Liminal Announces Voting Results of Its 2021 Annual and Special General Meeting of Shareholders (AGM)
May 17, 2021: Liminal BioSciences Reports First Quarter 2021 Financial Results
Mar 24, 2021: Liminal BioSciences Reports Fourth Quarter and Year End 2020 Financial Results
Jan 12, 2021: Liminal BioSciences receives FDA approval for its US-based plasma collection center
Nov 12, 2020: Liminal BioSciences reports third quarter financial results
Nov 10, 2020: Liminal Biosciences to Reschedule Reporting of Q3 2020 Results and Conference Call
Nov 06, 2020: Liminal Biosciences To Report Q3 2020 Results And Hold Conference Call
Sep 01, 2020: Liminal BioSciences announces new appointments to its board of directors
Aug 10, 2020: Liminal BioSciences reports financial results for Q2-2020
Jul 22, 2020: Liminal BioSciences to voluntarily delist from the Toronto stock exchange

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Liminal BioSciences Inc, Key Facts
Liminal BioSciences Inc, Key Employees
Liminal BioSciences Inc, Key Employee Biographies
Liminal BioSciences Inc, Major Products and Services
Liminal BioSciences Inc, History
Liminal BioSciences Inc, Other Locations
Liminal BioSciences Inc, Subsidiaries
Liminal BioSciences Inc, Key Competitors
Liminal BioSciences Inc, Ratios based on current share price
Liminal BioSciences Inc, Annual Ratios
Liminal BioSciences Inc, Annual Ratios (Cont...1)
Liminal BioSciences Inc, Interim Ratios
Liminal BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Liminal BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Liminal BioSciences Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Liminal BioSciences Inc, Performance Chart (2016 - 2020)
Liminal BioSciences Inc, Ratio Charts
Liminal BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Liminal BioSciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021